E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in previous studies
|
|
E.1.1.1 | Medical condition in easily understood language |
Advanced Parkinson's disease in subjects who have exhibited a persistent and positive effect to treatment in previous studies |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013113 |
E.1.2 | Term | Disease Parkinson's |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to provide, under well-controlled conditions,
continued access to LCIG treatment to subjects who have already participated in an
open-label efficacy and safety trial with the same treatment (S187.3.003, S187.3.004, or
any new Phase 3 open-label LCIG study initiated by the Sponsor), and in whom the need
for such continuation is indicated, as confirmed by periodic evaluation, until the product
is commercially available. |
|
E.2.2 | Secondary objectives of the trial |
To assess the long-term safety and tolerability of the LCIG therapeutic system by the
following:
● Physical examination, including weight
● Neurological examination
● Vital signs
● Resting ECGs
● Columbia Suicide-Severity Rating Scale (C-SSRS)
● Clinical laboratory assessments including biochemistry, hematology,
urinalysis, and special labs to monitor for vitamin deficiencies
● Concomitant medication usage
● Adverse event monitoring, including for the development of sleep attacks,
melanoma, or excessive impulsive behavior
● Monitoring complications of the infusion device
● Tolerability assessed by number of subjects who complete the study |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, subjects must meet the following criteria:
1. The subject should have completed participation in Study S187.3.003, S187.3.004, or any new Phase 3 open-label LCIG study initiated by the Sponsor; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG. For Canada, subjects will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.
2. The subject must understand the nature of the study and must provide written
informed consent prior to the conduct of any study related procedures. |
|
E.4 | Principal exclusion criteria |
Subjects meeting any of the exclusion criteria listed below at baseline must be excluded from participation in the study.
1. Medical, laboratory, psychiatric, or surgical issues deemed by the Investigator to be clinically significant, and which could confound the findings of the study, or interfere with the subject’s participation in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and Tolerability Assessments:
1. Adverse event monitoring (including sleep attacks, development of impulsive behavior and of melanoma)
2. Monitoring complications of the infusion device
Efficacy Assessments (for the subject’s continuity in the study):
1. Periodic assessment of the appropriateness for continuation in the study. The decision to continue is based on the Principle Investigator’s clinical judgment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Until commercial availability
|
|
E.5.2 | Secondary end point(s) |
Evaluation of physical exams, neurological exams, vitals, ECGs, clinical lab assessments, concomitant medication usage, monitoring complications of the infusion device, adverse event monitoring, tolerability assessed by the number of subjects who complete the study.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Until commercial availability
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Czech Republic |
Israel |
Italy |
New Zealand |
Poland |
Portugal |
Russian Federation |
Thailand |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as the date of the last visit of the last patient undergoing the trial (plus a mandatory follow-up of 30 days in case of a SAE) and/or the day on which the last patient of the study can be switched to the commercially available marketed product. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 8 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |